Currently, ongoing clinical trials, including Renal Denervation in Diabetes (NCT 02081989, conducted to investigate the effects of RDN on diabetes), Metabolic Syndrome Study (Renal Sympathetic Denervation in Metabolic Syndrome, NCT 01911078, performed to determine the effects of RDN on insulin resistance and MSNA in patients with metabolic syndrome), and others, which are evaluating the effects of sympathetic RDN on glucose metabolism and insulin sensitivity, will further define the applicability of RDN in T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.